Article
Biochemistry & Molecular Biology
Qiaoling Tong, Man Hu, Meixian Deng
Summary: MiR-10b can inhibit the occurrence and development of cervical cancer in rats by suppressing mTOR/P70S6K signaling, reducing the level of inflammation and oxidative stress, and increasing the level of immune factors.
CELLULAR AND MOLECULAR BIOLOGY
(2022)
Review
Oncology
Eunus S. Ali, Kangkana Mitra, Shamima Akter, Sarker Ramproshad, Banani Mondal, Ishaq N. Khan, Muhammad Torequl Islam, Javad Sharifi-Rad, Daniela Calina, William C. Cho
Summary: The PI3K-Akt-mTOR signaling pathway plays a crucial role in various biological activities. Targeting mTOR with rapamycin-derived compounds has proven effective in suppressing mTOR activity and reducing cancer cell growth.
CANCER CELL INTERNATIONAL
(2022)
Review
Immunology
Anne E. O'Shea, Franklin A. Valdera, Daniel Ensley, Todd R. Smolinsky, Jessica L. Cindass, Phillip M. Kemp Bohan, Annelies T. Hickerson, Elizabeth L. Carpenter, Patrick M. McCarthy, Alexandra M. Adams, Timothy J. Vreeland, Guy T. Clifton, George E. Peoples
Summary: Rapamycin inhibits mTOR signaling, exhibiting both immunosuppressive and immunostimulatory effects on innate and adaptive immune responses. The dose and administration schedule play a crucial role in modulating rapamycin's immunologic effects.
CLINICAL IMMUNOLOGY
(2022)
Article
Oncology
Haowei Wang, Yujia Chen, Qinzi Yuan, Lixia Chen, Peiling Dai, Xuenong Li
Summary: This study found that HRK is lowly expressed in colorectal cancer tissues. For the first time, it was shown that HRK promotes apoptosis and inhibits proliferation of colorectal cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway. HRK represents a potential target for the treatment of colorectal cancer.
FRONTIERS IN ONCOLOGY
(2022)
Review
Cell Biology
Mikhail Blagosklonny
Summary: This article proposes hallmarks of aging based on a hierarchical principle and the hyperfunction theory. It suggests that unlike cancer, aging is not a molecular disease, but rather a result of normal intracellular signaling pathways becoming hyperfunctional, leading to a range of age-related diseases.
Article
Biochemistry & Molecular Biology
Xiaoling Zhang, Hao Liu, Haidong Wang, Rongjie Zhao, Qian Lu, Yunlong Liu, Yicheng Han, Hongming Pan, Weidong Han
Summary: This study found that b3galt5 is highly expressed in hepatocellular carcinoma (HCC) and associated with poor prognosis. It promotes the proliferation and survival of HCC cells and activates the mTOR/p70s6k pathway to enhance glycolysis through O-linked glycosylation modification. Inhibition of p70s6k reduces glycolysis in b3galt5-overexpressing cells. This study uncovers a novel mechanism and potential therapy target for HCC.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2023)
Article
Cell Biology
Chen Yang, Yanchun Li, Wanye Hu, Xu Wang, Jiayu Hu, Chen Yuan, Chaoting Zhou, Hairui Wang, Jing Du, Ying Wang, Xiangmin Tong
Summary: TEOA inhibits proliferation and migration of pancreatic cancer cells by inducing mitochondrial dysfunction and ROS-dependent autophagic cell death, suggesting its potential as a promising therapeutic agent for pancreatic cancer.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Xue Yang, Zexuan Liu, Weiwei Tang, Uday P. Pratap, Alexia B. Collier, Kristin A. Altwegg, Rahul Gopalam, Xiaonan Li, Yaxia Yuan, Daohong Zhou, Zhao Lai, Yidong Chen, Gangadhara R. Sareddy, Philip T. Valente, Edward R. Kost, Suryavathi Viswanadhapalli, Ratna K. Vadlamudi
Summary: The study assessed the effectiveness of the inhibitor SMIP34 in treating ECa. SMIP34 significantly reduced cell viability, colony formation ability, and induced apoptosis in ECa cells. Mechanistic studies revealed that SMIP34 disrupted ribosomal biogenesis and new protein synthesis. Furthermore, SMIP34 enhanced the efficacy of mTOR inhibitors and reduced the growth of ECa xenografts.
MOLECULAR ONCOLOGY
(2023)
Article
Oncology
Li Pang, Xiaohan Chang
Summary: Resistance expression is positively correlated with pathological grade and lymph node metastasis in epithelial ovarian cancer, potentially promoting cell proliferation and migration through the mTOR signaling pathway.
Review
Chemistry, Medicinal
Suhail Ahmad Mir, Ashraf Dar, Saad Ali Alshehri, Shadma Wahab, Laraibah Hamid, Mohammad Ali Abdullah Almoyad, Tabasum Ali, Ghulam Nabi Bader
Summary: Mechanistic target of rapamycin (mTOR) is a protein kinase involved in regulating cellular processes through integration of different stimuli. Dysregulation of mTOR signalling pathways is considered a hallmark of cancer, making it an important target for anti-cancer therapeutics. This review discusses the current developments in mTOR signalling and the use of inhibitors to target this pathway.
Article
Oncology
Prabhakar Pitta Venkata, Yihong Chen, Salvador Alejo, Yi He, Bridgitte E. Palacios, Ilanna Loeffel, Junhao Liu, Uday P. Pratap, Gabrielle Gray, Sureshkumar Mulampurath Achuthan Pillai, Yi Zou, Zhao Lai, Takayoshi Suzuki, Suryavathi Viswanadhapalli, Srinath Palakurthi, Rajeshwar R. Tekmal, Ratna K. Vadlamudi, Edward Kost, Gangadhara R. Sareddy
Summary: The study revealed a strong synergistic effect between KDM1A inhibitors and mTOR inhibitors, showing significant reduction in cell viability and migration in EC cells with combination therapy. Inhibition of KDM1A decreased the activation of the mTOR signaling pathway and blocked rapamycin-induced feedback activation of Akt. The combination therapy could potentially serve as an effective targeted treatment for EC patients.
Article
Dermatology
A. J. Duran-Romero, J. C. Hernandez-Rodriguez, J. Ortiz-Alvarez, J. J. Dominguez-Cruz, M. T. Monserrat-Garcia, J. Conejo-Mir Sanchez, J. Bernabeu-Wittel
Summary: Oral sirolimus shows good efficacy and safety in treating high-flow vascular malformations, with most patients experiencing partial relief and tolerating the treatment well. It can be a useful option for long-term stabilization of patients with high-flow vascular malformations.
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2022)
Article
Nanoscience & Nanotechnology
Donghua Wang, Xiaoli Liu, Shixiong Gong, Yijuan Jia, Ping Wang
Summary: This study demonstrates the mechanism of miR-488-5p carried by magnetic carbon nanotubes (MAGCNTs) in restraining lymphatic metastasis in cervical cancer through induction of mTOR/P70S6K signaling pathway. The results show that quantity of lymphatic metastasis was lowest in the miR-488-5p carrier group, with highest expression of miR-488-5p and inhibited activity of the mTOR/P70S6K signaling pathway.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Lucia Lisi, Michela Pizzoferrato, Gabriella Maria Pia Ciotti, Maria Martire, Pierluigi Navarra
Summary: Initially used as immunosuppressants in therapy, selective inhibitors of mTORC1 have now been approved for the treatment of solid tumors. Non-selective mTOR inhibitors are being developed in preclinical and clinical studies in oncology to overcome limitations of selective inhibitors, such as tumor resistance. In this study, we compared the effects of a non-selective mTOR inhibitor, sapanisertib, with rapamycin in glioblastoma cell lines and microglia, and found overlapping and diverging effects, especially in the activation of tumor-associated microglia.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Nanoscience & Nanotechnology
Yi-Qing Chen, Wen-Ting Zhu, Cai-Yan Lin, Zhong-Wen Yuan, Zhen-Hua Li, Peng-Ke Yan
Summary: This study successfully constructed a liposome delivery system for rapamycin to enhance its efficacy in treating colorectal cancer. The rapamycin liposomes showed superior antitumor effects compared to free rapamycin both in vitro and in vivo, and were able to synergistically enhance the efficacy of 5-FU in colorectal cancer via the Akt/mTOR and P53 pathways.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Article
Oncology
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L. Giuntoli II, Sarah H. Kim, Fiona Simpkins, Lainie Martin, Emily M. Ko
Summary: The prevalence of ERBB2 gene amplification was investigated among patients with gynecologic malignancies. The study found that ERBB2 amplification is frequently encountered in uterine serous carcinoma and mucinous ovarian carcinoma, but less common in endometrioid endometrial carcinoma.
GYNECOLOGIC ONCOLOGY
(2024)